3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Children's Health - Cancer -

Benefit confirmed in “bubble boy” treatment

Children's Health • • CancerJul 22, 10

A 10-year study of nine boys born without the ability to ward off germs has found that gene therapy is an effective long-term treatment, but it carries a price: four of them developed leukemia.

The technique is designed to help boys with X-linked severe combined immunodeficiency disease, or SCID, a rare mutation that prevents the body from making mature T cells or natural killer cells, which are vital tools for fighting infections.

Without a bone marrow transplant, which works best with a matching donor, such “bubble babies” have to live in germ-free environments and usually die within a year. Doctors hope gene therapy will work when no donor is available.

But its success has been limited by the threat of leukemia, and the new study looks at the long-term impact of a treatment that the researchers last used in 2002.

The team, led by Salima Hacein-Bey-Abina of the Paris Descartes University, reported in the New England Journal of Medicine that the treatment provided a long-term cure for SCID, in most cases.

“All children except one, including the three survivors of T-cell acute leukemia, could live normally in a nonprotected environment and cope with microorganisms without harmful consequences while growing normally,” they concluded.

The median age of the boys when they got the gene therapy was seven months. The one death was from leukemia.

Leukemia is much easier to treat in young children than SCID. The success rate is usually 90 percent or more.

The team said the research has set the stage for tests of other types of gene therapy that use safer methods for correcting defective DNA.

SOURCE:  New England Journal of Medicine, July 22, 2010.

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site